Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

NCT04876248 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

BIOLOGICAL: Belantamab Mafodotin
DRUG: Lenalidomide

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]